Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 11:18 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,868 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: BE-FAST Clear all
Terminated No phase listed Observational Accepts healthy volunteers

Pilot Study Characterizing Adipose Tissue Leukocytes by Flow Cytometry/Microscopy in Lean, Obese and Psoriatic Subjects

NCT01856647
View directory record Official record
Conditions
Psoriasis, Obesity
Interventions
Adipose tissue biopsy (fat biopsy)
Procedure
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 21, 2015 · Synced Oct 30, 2026, 11:18 PM EDT
Completed Not applicable Interventional

Diabetic Foot Ulcer (DFU) Rapid Pathogen Identification

NCT06569238
View directory record Official record
Conditions
Diabetic Foot Ulcer, Diabetes Mellitus, Wound
Interventions
Conventional bacterial culture, Rapid diagnostic group using mNGS technology
Diagnostic Test · Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 30, 2026, 11:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of Relative Bioavailability and Effect of Food on Capsule and Tablet Formulations of TP-3654

NCT06389955
View directory record Official record
Conditions
Healthy
Interventions
TP 3654
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 30, 2026, 11:18 PM EDT
Not listed Phase 4 Interventional

Weight Loss Benefits of Rifaximin in an Intermittent Fasting Diet

NCT04674176
View directory record Official record
Conditions
Weight Loss
Interventions
Rifaximin
Drug
Lead sponsor
Bayhealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dover, Delaware
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 30, 2026, 11:18 PM EDT
Terminated Phase 2 Interventional

A Study to Assess the Efficacy and Safety of the VEGFR-FGFR Inhibitor, Lucitanib, Given to Patients With Advanced/Metastatic Lung Cancer and FGF, VEGF, or PDGF Related Genetic Alterations

NCT02109016
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer, NSCLC, Small Cell Lung Cancer, SCLC, Lung Cancer, Advanced Lung Cancer, Metastatic Lung Cancer, Stage IV Lung Cancer
Interventions
Lucitanib
Drug
Lead sponsor
Clovis Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 30, 2026, 11:18 PM EDT
Completed Phase 3 Interventional Results available

Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

NCT00103506
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Bortezomib (VELCADE), Doxorubicin hydrochloride (DOXIL/CAELYX)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
646 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2014
U.S. locations
28
States / cities
Alabaster, Alabama • Surprise, Arizona • Berkeley, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 30, 2026, 11:18 PM EDT
Recruiting Not applicable Interventional

Molecular Genetic Mechanisms of Infantile Epilepsies and the Impact of Genetic Diagnosis

NCT06701084
View directory record Official record
Conditions
Neonatal Epilepsy, Infantile Epilepsy
Interventions
Genomic Sequencing
Genetic
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 30, 2026, 11:18 PM EDT
Enrolling by invitation Not applicable Interventional

Effect of Novel High Dissolving Transitional Foods

NCT06522958
View directory record Official record
Conditions
Craniofacial Surgery
Interventions
High Dissolving Transitional Food
Dietary Supplement
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Months to 18 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 30, 2026, 11:18 PM EDT
Active, not recruiting Not applicable Interventional

12-hour Time Limited Feeding in Critical Care

NCT06741761
View directory record Official record
Conditions
Critical Illness
Interventions
12-hour time-restricted feeding (TRF12), Continuous 24 hour feeding (CONT24).
Other
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 30, 2026, 11:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

How Animal and Plant Protein Shakes Change the Body's Nutrient and Health Responses

NCT07121010
View directory record Official record
Conditions
Cardiometabolic Health
Interventions
Animal-Based Protein Smoothie, Plant-Based Protein Smoothie, Plant-Based Protein Smoothie with Leucine
Dietary Supplement
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 30, 2026, 11:18 PM EDT
Completed Not applicable Interventional

BRIDGE: Improving HIV Service Delivery for People Who Inject Drugs

NCT02796027
View directory record Official record
Conditions
Human Immunodeficiency Virus, Substance Abuse, Intravenous
Interventions
BRIDGE
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
616 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Oct 30, 2026, 11:18 PM EDT
Not yet recruiting Not applicable Interventional

Differences in Mechanistic Measures (Oxytocin and Cortisol) of Therapeutic Alliance Between A Talk-Based Therapy and Soft-Tissue Mobilization in Individuals With Chronic Spinal Pain

NCT06987786
View directory record Official record
Conditions
Spine, Low Back Pain, Neck Pain
Interventions
Massage, Talk-based therapy
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 30, 2026, 11:18 PM EDT
Enrolling by invitation Not applicable Interventional

Electrochemical and Electrophysiological Study

NCT05273970
View directory record Official record
Conditions
Cognition, Medically Intractable Epilepsy
Interventions
Behavioral testing under intracranial monitoring
Other
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 30, 2026, 11:18 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation

NCT03130556
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Glasdegib, High Fat, High Calorie Meal, Rabeprazole
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 30, 2026, 11:18 PM EDT
Completed Phase 4 Interventional Results available

Buprenorphine Extended-Release Subcutaneous Injection (RBP-6000) in High-risk Users

NCT04995029
View directory record Official record
Conditions
Moderate to Severe Opioid-use Disorder
Interventions
Transmucosal Buprenorphine, Extended-release Buprenorphine
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
785 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
28
States / cities
Garden Grove, California • Panorama City, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 30, 2026, 11:18 PM EDT
Recruiting No phase listed Observational

Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

NCT02602769
View directory record Official record
Conditions
Childhood Obesity, Morbid Obesity
Interventions
Transcriptome profiling
Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
2 Years to 20 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
2
States / cities
Boston, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Oct 30, 2026, 11:18 PM EDT
Completed Phase 4 Interventional Results available

SUBLOCADE Rapid Initiation Extension Study

NCT04060654
View directory record Official record
Conditions
Opioid Use Disorder, Severe, Opioid Use Disorder, Moderate
Interventions
Sublocade
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Oct 30, 2026, 11:18 PM EDT
Terminated Phase 2 Interventional

HT-100 Long-term Study in DMD Patients Who Completed HALO-DMD-02

NCT02525302
View directory record Official record
Conditions
Duchenne Muscular Dystrophy
Interventions
HT-100
Drug
Lead sponsor
Akashi Therapeutics
Industry
Eligibility
6 Years to 20 Years · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
5
States / cities
Sacramento, California • Baltimore, Maryland • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 30, 2026, 11:18 PM EDT
Completed Early Phase 1 Interventional

Rapid Infusion Rituximab, Hematologic, Oncologic, and Rheumatologic Disorders

NCT02484053
View directory record Official record
Conditions
Hematologic Disorders, Oncologic Disorders, Rheumatologic Disorders
Interventions
Rituximab
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
1 Year to 19 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 30, 2026, 11:18 PM EDT
Completed No phase listed Observational

Brain Perfusion and Hemodynamic Stability in Patients Undergoing Radiofrequency Ablation of Ventricular Tachycardia

NCT01695551
View directory record Official record
Conditions
Ventricular Tachycardia
Interventions
Data Collection Forms
Other
Lead sponsor
Dhanunjaya Lakkireddy, MD, FACC
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 30, 2026, 11:18 PM EDT
Recruiting Phase 1Phase 2 Interventional

Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer

NCT07736937
View directory record Official record
Conditions
Ovarian Cancer
Interventions
TUB-040 + Carbo + BEV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Los Angeles, California • East Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Oct 30, 2026, 11:18 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

COVID-19 iCura SARS-CoV-2 Ag OTC: Clinical Evaluation

NCT05555030
View directory record Official record
Conditions
SARS-CoV-2 Infection, COVID-19
Interventions
iCura COVID-19 Antigen Rapid Home Test, RT-PCR Test
Device · Diagnostic Test
Lead sponsor
New Day Diagnostics
Network
Eligibility
2 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
2
States / cities
Anaheim, California • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Oct 30, 2026, 11:18 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Investigating Individual Differences in Speech Motor Skills in Neurotypical Speakers and Persons With Disordered Speech

NCT07459803
View directory record Official record
Conditions
Stuttering, Developmental, Dyslexia, Healthy Participants
Interventions
Unpredictable auditory feedback perturbation: 2 behavioral sessions, Unpredictable auditory feedback perturbation during tCS: 3 behavioral sessions, Sustained F1 auditory feedback perturbation, Sustained F0 auditory feedback perturbation, Reflexive somatosensory perturbation, Anodal tCS targeting pSTG and vSSC, Anodal tCS targeting left or right vPMC, Sham tCS targeting pSTG or vSSC, Sham tCS targeting left vPMC or right vPMC
Behavioral · Other
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 30, 2026, 11:18 PM EDT
Not listed Phase 2Phase 3 Interventional

Safety and Effectiveness of the PXL Platinum 330 System With Riboflavin Solution for Previously Untreated Corneal Ulcers

NCT05255107
View directory record Official record
Conditions
Keratitis, Corneal Ulcer
Interventions
Standard of Care Therapy + CXL + Riboflavin 0.23% L Solution, Standard of Care Therapy + Sham CXL + Artificial Tears
Combination Product · Other
Lead sponsor
Peschke GmbH
Industry
Eligibility
18 Years and older
Enrollment
468 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
12
States / cities
Littleton, Colorado • Fort Myers, Florida • Tampa, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2022 · Synced Oct 30, 2026, 11:18 PM EDT